Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus apatinib versus paclitaxel plus apatinib as second-line treatment for advanced gastric cancer
ChiCTR2000028991Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Sep 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of paclitaxel and Rivoceranib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoints: progression-free survival and disease control rate. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
paclitaxelRivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000028991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028991.